Casma Therapeutics

Casma Therapeutics is a biotechnology company engaging the autophagy system to provide innovative new medicines.

Casma's mission is to deliver novel therapeutics through a deeper understanding and engineering of autophagy.

Casma was founded in 2018 by Andrea Ballabio, Beth Levine, James Hurley and Herbert “Skip” Virgin. The company is headquartered in Cambridge, Massachusetts.

 

Casma is developing novel cellular degradation approaches based on the autophagy pathway to open new target areas for drug discovery and development that will profoundly impact the lives of patients.

 

Casma established the PHLYT™ technology platform to expand targeted degradation in ways previously unimagined. PHLYT reprograms autophagy to generate autophagosomes around these disease targets resulting in degradation.

 

Casma uses several approaches to intervene at strategic points in the autophagy-lysosome system to improve the cellular process of enhancing membrane repair and clearing out unwanted proteins, aggregates, organelles and invading pathogens.

 

Casma is backed by Third Rock Ventures, Amgen Ventures, The Column Group, Eventide Asset Management, Astellas Venture Management, Eisai Co., Schroder Adveq, Euclidean Capital, Mirae Asset, Ono Venture Investment, and others. The company closed a $46M Series C round on Nov 15, 2022. This brings Casma's total funding to $154.9M to date. 

 

 

  • Year founded: 2018
  • Funding Info: $154.9M over 5 Rounds (Latest Funding Type: Series C)
  • Yearly Revenue: NA
  • Employee Size: 11-50
  • Business Valuation: NA
  • City/Town: Cambridge
  • State: Massachusetts
  • Country: United States
Related businesses